FrancophonIA/ELRC3.0 huggingface dataset:
English: Both Committees confirmed their opinion that the effectiveness of Heparesc in the treatment of these disorders had not been sufficiently demonstrated.
Estonian: Mõlemad komiteed kinnitasid oma arvamust, et Heparesci efektiivsust nende häirete ravis ei ole piisavalt tõendatud.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom23 October 2015 EMA/684158/2015 EMEA/H/C/003750
Estonian: oktoober 2015 EMA/684158/2015 EMEA/H/C/003750
English: Heparesc is a medicine that contains living cells from the liver of a healthy donor which have been manipulated and then frozen for long-term storage.
Estonian: Heparesc on ravim, mis sisaldab terve doonori maksast pärit elusrakke, mida on töödeldud ja seejärel külmutatud pikaajaliseks säilitamiseks.
English: Heparesc was intended to help temporary management of these conditions in children until they are big enough to be given a liver transplant to cure them.
Estonian: Heparesci kavatseti kasutada nende seisundite ajutiseks leevendamiseks lastel, kuni nad on piisavalt suured, et seisundi lõplikuks ravimiseks saaks neile siirata maksa.
English: As a result, toxic waste products build up in the blood in the form of ammonia which can lead to brain damage, convulsions (fits), coma and death.
Estonian: Selle tulemusena kogunevad veres toksilised jääkained ammoniaagina, mis võib põhjustada ajukahjustust, krampe, koomat ja surma.
English: The company presented the results of two main studies involving a total of 20 children with urea cycle disorders in which the effects of Heparesc were compared with historical results in children who had not received Heparesc treatment.
Estonian: Ettevõte esitas kahe põhiuuringu tulemused, milles osales kokku 20 uureatsükli häiretega last ja milles võrreldi Heparesci toimeid varasemate tulemustega lastel, keda ei olnud ravitud Heparesciga.
English: Refusal of the marketing authorisation for Heparesc (human heterologous liver cells)
Estonian: Heparesci (inimese heteroloogsed maksarakud) müügiloa andmisest keeldumine
English: On 25 June 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Heparesc, intended for the treatment of urea cycle disorders.
Estonian: 25. juunil 2015 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades uureatsükli häirete raviks kasutatava ravimi Heparesc müügiloa andmisest keelduda.
English: This is a type of medicine containing cells or tissues that have been manipulated so that they can be used to cure, diagnose or prevent a disease.
Estonian: Somaatilise rakuteraapia ravim sisaldab rakke või kudesid, mida on töödeldud nii, et neid saab kasutada haiguse ravimiseks, diagnoosimiseks või ennetamiseks.
English: The specific urea cycle disorders for which Heparesc was intended to be used are called carbamoylphosphate synthetase 1 deficiency, ornithine transcarbamylase deficiency, argininosuccinate synthetase deficiency (citrullinaemia type 1), argininosuccinate lyase deficiency (argininosuccinic aciduria) and arginase deficiency (hyperargininaemia).
Estonian: Spetsiifilised uureatsükli häired, mille korral kavatseti kasutada Heparesci, on karbamoüülfosfaadi süntetaas-1 vaegus, ornitiini transkarbamülaasi vaegus, argininosuktsinaadi süntetaasi vaegus (I tüüpi tsitrullineemia), argininosuktsinaadi lüaasi vaegus (argininosuktsiinatsiduuria) ja arginaasi vaegus
English: The main measures of effectiveness were the change in the levels of 13C-labelled urea production (a test intended to show the ability to produce urea) after treatment as compared to before, and the number, length and severity of any episodes of high ammonia in the blood during the studies.
Estonian: Efektiivsuse põhinäitajad olid 13C-märgistatud uurea tekkimise muutus (analüüs, mis näitab, kuidas maksas tekib uureat) pärast ravi võrreldes ravieelsega ning uuringute ajal esinenud vere suure ammoniaagisisalduse episoodide arv, pikkus ja raskusaste.
English: Heparesc is made of liver cells from an organ donor who can produce the enzyme that is missing in patients with urea cycle disorders.
Estonian: Heparesc on valmistatud elundidoonori maksarakkudest, mis suudavad tekitada uureatsükli häiretega patsientidel puuduvat ensüümi.
English: The company informed the CHMP that the refusal had no consequences for patients in clinical trials or compassionate use programmes.
Estonian: Ettevõte teatas inimravimite komiteele, et keeldumine ei mõjuta kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente.
English: Heparesc was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 14 September 2007 for ornithine transcarbamylase deficiency, and 17 December 2010 for the other above conditions.
Estonian: Heparesc nimetati 14. septembril 2007 ornitiini transkarbamülaasi vaeguse harvikravimiks ja 17. detsembril 2010 teiste loetletud seisundite harvikravimiks.
English: During the re-examination the CAT and CHMP looked again at the data from the company, and also consulted experts in the treatment of urea cycle disorders.
Estonian: Taasläbivaatamise ajal vaatasid uudsete ravimeetodite komitee ja inimravimite komitee uuesti läbi ettevõtte esitatud andmed ning konsulteerisid uureatsükli häirete ravi spetsialistidega.
English: Although taking into account the challenges of developing the medicine, including the difficulty of enrolling patients due to the rarity of the disease, the CHMP therefore concluded that the benefits of Heparesc did not outweigh its risks and maintained the previous recommendation that the medicine be refused marketing authorisation.
Estonian: Kuigi inimravimite komitee arvestas ravimi väljatöötamise raskusi, sealhulgas patsientide uuringusse kaasamise raskusi haiguse harulduse tõttu, järeldas inimravimite komitee, et Heparesci kasulikkus ei ületa selle riske, ja jäi eelmise soovituse juurde ravimi müügiloa andmisest keelduda.
English: Therefore, at the time of the initial evaluation, the CHMP was of the opinion that the benefits of Heparesc did not outweigh its risks and recommended that it be refused marketing authorisation.
Estonian: Seetõttu oli inimravimite komitee esmase hindamise ajal arvamusel, et Heparesci kasulikkus ei ole suurem kui sellega kaasnevad riskid, ja soovitas müügiloa andmisest keelduda.
English: How is Heparesc expected to work?
Estonian: Milline on Heparesci eeldatav toime?
English: Because Heparesc is an advanced therapy medicine, it was assessed by the Committee for Advanced Therapies (CAT).
Estonian: Et Heparesc on uudne ravim, hindas seda uudsete ravimeetodite komitee.
English: The CHMP had concerns about the design and conduct of the studies, which cast doubt on their results and whether these could have occurred by chance.
Estonian: Inimravimite komiteel tekkis küsimusi seoses uuringute ülesehituse ja korraldusega, mis vähendavad uuringutulemuste usaldusväärsust ja viitavad võimalusele, et tulemused olid juhuslikud.
English: These are rare inborn conditions in which the liver does not produce particular enzymes involved in removing nitrogen from the body via a substance called urea.
Estonian: Need on harvaesinevad kaasasündinud seisundid, mille korral maksas ei teki teatud ensüüme, mis osalevad lämmastiku eemaldamises organismist seda uureaks muundades.
English: When the medicine is injected into the portal vein leading to the liver, some of the liver cells it contains are expected to settle in the recipient's liver and start producing the missing liver enzyme, thus helping to reduce the symptoms of the disease.
Estonian: Ravimi süstimisel maksa viivasse värativeeni eeldatakse, et osa ravimis sisalduvaid maksarakke jääb patsiendi maksa ja hakkab tekitama puuduvat maksaensüümi, aidates sellega leevendada haiguse sümptomeid.
English: The medicine was to be given by slow injection through a tube inserted by a surgical procedure into the portal vein (a vein leading directly to the patient's liver).
Estonian: Ravimit kavatseti manustada aeglase süstina, värativeeni (maksa suunduvasse veeni) kirurgilise protseduuriga paigaldatud kateetri kaudu.
English: Heparesc was to be used for the treatment of children from birth up to 3 years of age with specific urea cycle disorders.
Estonian: Heparesci kavatseti kasutada spetsiifiliste uureatsükli häiretega laste raviks sünnist 3 aasta vanuseni.
English: The effects of Heparesc were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Heparesci toimet muude katsetega.
English: Taking into account the assessments performed by the CAT, the CHMP concluded that Heparesc could not be approved for the treatment of children with urea cycle disorders.
Estonian: Uudsete ravimeetodite komitee hinnangute alusel järeldas inimravimite komitee, et Heparesci ei saa uureatsükli häiretega laste raviks heaks kiita.
English: What was Heparesc expected to be used for?
Estonian: Milleks kavatseti Heparesci kasutada?
English: In addition, the CHMP had concerns about the clinical relevance of the results of the tests that measured the ability to produce urea.
Estonian: Lisaks tekkis inimravimite komiteel küsimusi, kas uurea tekkimist mõõtvate analüüside tulemused on kliiniliselt asjakohased.
English: Heparesc was developed as a type of advanced therapy medicine called a ‘somatic cell therapy product'.
Estonian: Heparesc on somaatilise rakuteraapia ravimite hulka kuuluv uudne ravim.
English: EU number
Estonian: Müügiloa nr Euroopa Liidus Ravimi väljamõeldud nimetus
English: Other sections
Estonian: Muud lõigud
English: The European Commission issued a decision on 21 February 2011.
Estonian: Euroopa Komisjon tegi otsuse 21. veebruaril 2011.
English: What is Tazocin?
Estonian: Mis on Tazocin?
English: Tazocin is authorised in the EU via national procedures.
Estonian: Tazocin on Euroopa Liidus saanud müügiloa riiklike menetluste kaudu.
English: Why was Tazocin reviewed?
Estonian: Miks vaadati Tazocini andmed uuesti läbi ?
English: Tazocin is also available in the EU under other trade names: Tazobac, Tazocel, Tazocilline and Tazonam.
Estonian: Tazocini turustatakse Euroopa Liidus ka kaubanduslike nimetuste Tazobac, Tazocel, Tazocilline ja Tazonam all.
English: The Committee also harmonised other sections of the SmPC including the sections on contraindications, special warnings and pregnancy and lactation.
Estonian: Inimravimite komitee ühtlustas ka ravimi omaduste kokkuvõtte muud lõigud, sealhulgas vastunäidustused, erihoiatused ning rasedust ja imetamist käsitlevad lõigud.
English: On 12 June 2009, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Tazocin in the EU.
Estonian: 12. juunil 2009 tegi Euroopa Komisjon inimravimite komiteele esildise, et ühtlustada Tazocini müügiload Euroopa Liidus.
English: The European Medicines Agency has completed a review of Tazocin.
Estonian: Euroopa Ravimiamet on lõpetanud Tazocini kohta tehtud taotluse läbivaatamise.
English: The CHMP agreed that Tazocin should be used to treat the following infections in adults and adolescents:
Estonian: Inimravimite komitee leppis kokku, et Tazocini tohib kasutada täiskasvanutel ja noorukitel järgmiste infektsioonide raviks:
English: Tazocin is a medicine that contains the active substances piperacillin and tazobactam.
Estonian: Tazocin on ravim, mis sisaldab toimeainetena piperatsilliini ja tasobaktaami.
English: The company that markets these medicines is Pfizer.
Estonian: Neid ravimeid turustab Pfizer.
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Estonian: Esitatud andmete hindamise ja inimravimite komitees toimunud teadusliku arutelu põhjal jõudis inimravimite komitee järeldusele, et ravimi omaduste kokkuvõtted, märgistus ja pakendi infoleht tuleb Euroopa Liidus ühtlustada.
English: • complicated skin and soft tissue infections, including diabetic foot infections.
Estonian: • naha ja pehmekudede tüsistunud infektsioonid, sealhulgas diabeediga seotud jalainfektsioonid.
English: It is used to treat a wide range of bacterial infections.
Estonian: Tazocini kasutatakse mitmesuguste bakteriaalsete infektsioonide raviks.
English: The dose for children is 80 mg piperacillin /10 mg tazobactam per kilogram body weight every six hours for neutropenic children and 100 mg piperacillin /12.5 mg tazobactam per kg body weight every eight hours for children with complicated intra-abdominal infections.
Estonian: Neutropeeniaga lastel on soovitatav annus 80 mg piperatsilliini / 10 mg tasobaktaami kilogrammi kehakaalu kohta iga 6 tunni järel ning kõhuõõne tüsistunud infektsioonidega lastel 100 mg piperatsilliini / 12,5 mg tasobaktaami kilogrammi kehakaalu kohta iga 8 tunni järel.
English: Tazocin may also be used to manage children, adolescents and adults with neutropenia (low levels of neutrophils, a type of white blood cell) who also have fever suspected to be caused by bacterial infection.
Estonian: Tazocini tohib kasutada ka neutropeeniaga (teatud vererakkude neutrofiilide väike sisaldus veres) laste, noorukite ja täiskasvanute raviks, kellel esineb palavik, mille põhjuseks peetakse bakteriaalset infektsiooni.
English: Questions and answers on Tazocin and associated names (piperacillin and tazobactam, 2/0.25 g and 4/0.5 g powder for solution for infusion)
Estonian: Teave Tazocini ja sarnaste nimetuste kohta (piperatsilliin ja tasobaktaam, 2/0,25 g ja 4/0,5 g infusioonilahuse pulber)
English: Tazocin can also be used in adults to treat bacteraemia (bacteria in the blood) that is associated with or suspected to be associated with the infections listed above.
Estonian: Tazocini tohib kasutada täiskasvanud patsientidel veel baktereemia (bakterite esinemine veres) raviks, mis on või võib olla tingitud eelpool nimetatud infektsioonidest.
English: For severe pneumonia and bacterial infections in neutropenic patients, the recommended dose is 4 g piperacillin /0.5 g tazobactam given every six hours.
Estonian: Raskekujulise pneumoonia ja bakteriaalsete infektsioonide korral on neutropeeniaga patsientidel soovitatav annus 4 g piperatsilliini / 0,5 g tasobaktaami iga 6 tunni järel.
English: Beta-lactamases break down beta-lactam antibiotics such as piperacillin, making the bacteria resistant to these medicines.
Estonian: Beetalaktamaasid lagundavad beetalaktaamide rühma antibiootikume, nagu piperatsilliin, muutes bakterid nende suhtes resistentseteks.
English: Questions and answers on Tazocin and associated names (piperacillin and tazobactam, 2/0.25 g and 4/0.5 g powder for solution for infusion) EMA/656918/2010
Estonian: Teave Tazocini ja sarnaste nimetuste kohta (piperatsilliin ja tasobaktaam, 2/0,25 g ja EMA/725532/2010
English: In adults and adolescents the usual dose is 4 g piperacillin /0.5 g tazobactam given every eight hours.
Estonian: Täiskasvanute ja noorukite tavaline annus on 4 g piperatsilliini / 0,5 g tasobaktaami iga 8 tunni järel.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Tazocin in the European Union (EU).
Estonian: EMA inimravimite komitee jõudis järeldusele, et Tazocini määramise teave tuleb Euroopa Liidus ühtlustada.
English: By blocking the action of beta-lactamases, tazobactam stops bacteria from being resistant to piperacillin, thereby making piperacillin more effective at killing them.
Estonian: Beetalaktamaaside toime blokeerimisega ennetab tasobaktaam bakterite muutumist piperatsilliini suhtes resistentseks, mistõttu on piperatsilliin bakterite hävitamisel efektiivsem.
English: This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
Estonian: Seetõttu on ravimi näidustused, ravimi omaduste kokkuvõtted, märgistus ja pakendi infoleht Tazocini turustavates liikmesriikides erinevad.
English: • severe pneumonia (infection of the lungs), including infections acquired in hospital or by patients on a mechanical ventilator
Estonian: • raske pneumoonia (kopsupõletik), sh haiglatekkene või ventilaatorravitekkene infektsioon;
English: Piperacillin is an antibiotic that belongs to the group ‘beta-lactams'.
Estonian: Piperatsilliin on beetalaktaamide rühma kuuluv antibiootikum.
English: Tazocin can be used to treat complicated intra-abdominal infections in children aged from two to 12 years.
Estonian: Tazocini tohib kasutada 2…12-aastastel lastel kõhuõõne tüsistunud infektsioonide raviks.
English: It works by attaching to proteins on the surface of bacteria.
Estonian: Piperatsilliin seondub bakterite pinnal olevate valkudega.
English: • complicated urinary tract infections, including pyelonephritis (kidney infection)
Estonian: • kuseteede tüsistunud infektsioonid, sealhulgas püelonefriit (neerupõletik);
English: Tazocin was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Estonian: Inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste koordineerimisrühm nimetas Tazocini ühtlustamist vajavaks ravimiks.
English: • complicated intra-abdominal infections (infections within the abdomen)
Estonian: • kõhuõõnesisesed tüsistunud infektsioonid;
English: Tazobactam blocks the action of bacterial enzymes called beta-lactamases.
Estonian: Tasobaktaam blokeerib bakteriensüümide beetalaktamaaside toime.
English: Observed data 257/295
Estonian: Vaadeldud andmed 257/295
English: NC= Failure
Estonian: NC = ebaõnnestumine
English: Component of a multipack, can't be sold separately.
Estonian: Mitmikpakendi osa, ei tohi müüa eraldi.
English: - This medicine has been prescribed for you or your child only.
Estonian: - Ravim on välja kirjutatud üksnes teile või teie lapsele.
English: * Body surface area can be calculated with the following equation:
Estonian: *Kehapindala on võimalik välja arvutada järgmise valemi alusel:
English: Currently available data are described in section 5.2 but no recommendation on a posology can be made.
Estonian: Praegu olemasolevad andmed on kirjeldatud lõigus 5.2, kuid annustamissoovitusi ei saa anda.
English: Your doctor will discuss with you and determine which medicines are best for you.
Estonian: Teie arst arutab seda teiega ja määrab teile sobivaimad ravimid.
English: Thirty-nine patients (39%) discontinued the study, including 16 (16%) discontinuations due to adverse events, one of which was associated with a death.
Estonian: Kolmkümmend üheksa patsienti (39%) katkestasid uuringu, sh 16 (16%) katkestasid kõrvaltoimete tõttu, millest üks oli seotud surmaga.
English: Events noted as having frequency “Not known” were identified via post-marketing surveillance.
Estonian: Kõrvaltoimetest, mille sageduseks on märgitud ”teadmata”, teavitati turuletulekujärgse järelvalve käigus.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 January 2016
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 14/01/2016
English: HMG Co-A Reductase Inhibitors
Estonian: HMG Co-A reduktaasi inhibiitorid
English: Around 85% of patients had a viral load of < 100,000 copies/ml.
Estonian: Umbes 85%-l patsientidest oli viiruskoormus < 100 000 koopiat/ml.
English: The increased digoxin level may lessen over time as Pgp induction develops.
Estonian: Tõusnud digoksiini tasemed võivad aja jooksul väheneda, kui toimub Pgp indutseerimine.
English: Stevens-Johnson syndrome, erythema multiforme
Estonian: Stevensi-Johnsoni sündroom, multiformne erüteem
English: Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100) and not known (cannot be estimated from the available data).
Estonian: Igas esinemissageduse grupis on kõrvaltoimed toodud tõsiduse vähenemise järjekorras: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100) ja teadmata (ei saa hinnata olemasolevate andmete alusel).
English: Conclusions regarding the relevance of particular mutations or mutational patterns are subject to change with additional data, and it is recommended to always consult current interpretation systems for analysing resistance test results.
Estonian: Järeldused teatud kindlate mutatsioonide või mutatsioonimustrite tähtsuse kohta võivad täiendavate andmete saamisel muutuda ning resistentsustestide tulemuste analüüsimisel on soovitatav alati tutvuda kehtivate resistentsuse tõlgendamise süsteemidega.
English: Hypromellose Titanium dioxide (E171) Macrogol
Estonian: Titaandioksiid (E171) Makrogool
English: Like all medicines, lopinavir/ritonavir can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka lopinaviir/ritonaviir põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: Mylan SAS 117 Allee des Parcs 69800 Saint-Priest France
Estonian: Mylan SAS 117 Allee des Parcs 69800 Saint-Priest Prantsusmaa
English: HDPE bottle: After first opening, use within 120 days.
Estonian: HDPE-pudel: pärast esmast avamist kasutada 120 päeva jooksul.
English: Other forms of this medicine may be more suitable for children; ask your doctor or pharmacist.
Estonian: Teised ravimvormid võivad paremini sobida lastele; pidage nõu oma arsti või apteekriga.
English: HCV protease inhibitors Boceprevir 800 mg three times daily
Estonian: HCV proteaasi inhibiitorid Botsepreviir 800 mg kolm korda ööpäevas
English: When you travel or need to stay in the hospital make sure you will have enough lopinavir/ritonavir to last until you can get a new supply.
Estonian: Kui lähete reisima või peate minema haiglasse, veenduge, et teil kaasas on piisavalt lopinaviiri/ritonaviiri, millest jätkub järgmise võimaluseni ravimit osta.
English: − Lopinavir/ritonavir should always be taken every day to help control your HIV infection, no matter how much better you feel.
Estonian: - Lopinaviiri/ritonaviiri peab alati võtma kaks korda ööpäevas, et aidata hoida kontrolli all teie HIV infektsiooni, vaatamata sellele kui hästi te ennast tunnete.
English: Afatinib: AUC: ↑ Cmax: ↑
Estonian: Afatiniib: AUC: ↑ Cmax: ↑
English: Pharmacotherapeutic group: antivirals for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR10
Estonian: Farmakoterapeutiline rühm: viirusvastased ained süsteemseks kasutamiseks, viirusvastaste ainete kombinatsioonid HIV-infektsiooni raviks, ATC kood: J05AR10.
English: Patients were administered either the tablet or the soft capsule formulation for 8 weeks, after which all patients were administered the tablet formulation once daily or twice daily for the remainder of the study.
Estonian: Patsientidele manustati tabletti või pehmet kapslit 8 nädalat, pärast mida manustati ülejäänud uuringu jooksul kõikidele patsientidele tabletti üks või kaks korda ööpäevas.
English: Postpartum n = 17**
Estonian: Pärast sünnitust n = 17**
English: − You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy.
Estonian: - Selle ravimi võtmise ajal võite siiski HIV nakkust edasi anda, kuigi efektiivne retroviirusvastane ravi vähendab seda riski.
English: This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'.
Estonian: Ravim sisaldab vähem kui 1 mmol (23 mg) naatriumi ühes tabletis, see tähendab põhimõtteliselt „naatriumivaba“.
English: Cmax: ↓ (relative to indinavir 800 mg TID alone)
Estonian: Cmax: ↓ (võrrelduna indinaviir 800 mg TID üksi)
English: − If you cannot contact your doctor, go to the hospital.
Estonian: - Kui te ei saa oma arsti kätte, pöörduge lähimasse haiglasse.
English: − weight gain.
Estonian: -kaalu alusel.